Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Susumu Okano"'
Autor:
Masanobu Sato, Tomohiro Enokida, Takao Fujisawa, Susumu Okano, Naohiro Takeshita, Nobukazu Tanaka, Hideki Tanaka, Atsushi Motegi, Sadamoto Zenda, Takeshi Shinozaki, Kazuto Matsuura, Ryuichi Hayashi, Tetsuo Akimoto, Makoto Tahara
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe significance of induction chemotherapy (IC) in the treatment of squamous cell carcinoma of the head and neck (SCCHN) with unresectable locoregional recurrence after curative surgery has not been clarified. The aim of this study was to e
Externí odkaz:
https://doaj.org/article/5697b67731264e01bfe02545996835e8
Autor:
Yuta Hoshi, Tomohiro Enokida, Shingo Tamura, Torahiko Nakashima, Susumu Okano, Takao Fujisawa, Masanobu Sato, Akihisa Wada, Hideki Tanaka, Naohiro Takeshita, Nobukazu Tanaka, Ryutaro Onaga, Takuma Kishida, Hideoki Uryu, Shingo Sakashita, Takahiro Asakage, Makoto Tahara
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundOlfactory neuroblastoma (ONB) is a rare malignant tumor of the head and neck. Due to its rarity, standard systemic therapy for this condition has yet to be established. In particular, the use of immune checkpoint inhibitors (ICIs) for the r
Externí odkaz:
https://doaj.org/article/159b1d1219d8410983fabd24393b33ea
Autor:
Yuma Shibutani, Kazuko Tajiri, Shinya Suzuki, Tomohiro Enokida, Atsunobu Sagara, Susumu Okano, Takao Fujisawa, Fumiaki Sato, Tetsuro Yumoto, Motohiko Sano, Toshikatsu Kawasaki, Makoto Tahara
Publikováno v:
Cancer Medicine, Vol 12, Iss 22, Pp 20773-20782 (2023)
Abstract Background Hypertension is the most frequently occurring adverse event of lenvatinib, recognized relatively early in its course. However, the trend in blood pressure after the initiation of lenvatinib and the outcomes with antihypertensive t
Externí odkaz:
https://doaj.org/article/25332373f7da40b29df12ef342640d17
Autor:
Hideki Tanaka, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Nobukazu Tanaka, Naohiro Takeshita, Ryutaro Onaga, Yuta Hoshi, Akihisa Wada, Masanobu Sato, Yuri Ueda, Makoto Tahara
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundImmune checkpoint inhibitors (ICIs) are essential in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall response rate (ORR) is limited to 10-20%, and subsequent chemotherapy is criti
Externí odkaz:
https://doaj.org/article/ba07fb074d6240e3bcd6832f75fe358e
Autor:
Chihiro Matsuyama, Tomohiro Enokida, Yuri Ueda, Shinya Suzuki, Takao Fujisawa, Kazue Ito, Susumu Okano, Makoto Tahara
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundIn the phase 3 SELECT study, lenvatinib significantly improved prognostic outcomes vs. placebo in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). However, toxicity of lenvatinib is sometimes considerable and req
Externí odkaz:
https://doaj.org/article/63bc75baf0b64005be684685da22fb57
Autor:
Ai Horinouchi, Tomohiro Enokida, Shinya Suzuki, Hayato Kamata, Asumi Kaneko, Chihiro Matsuyama, Takao Fujisawa, Yuri Ueda, Kazue Ito, Susumu Okano, Toshikatsu Kawasaki, Makoto Tahara
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundPersistent opioid use frequently leads to substantial negative impacts on quality of life, and as the outlook for numerous cancer types continues to improve, these complications become increasingly crucial. It is essential to acknowledge th
Externí odkaz:
https://doaj.org/article/f96c0f2c26734cdeb24e1ec8e8880719
Autor:
Taigo Kato, Nobuaki Matsubara, Masaki Shiota, Masatoshi Eto, Takahiro Osawa, Takashige Abe, Nobuo Shinohara, Yota Yasumizu, Nobuyuki Tanaka, Mototsugu Oya, Koshiro Nishimoto, Takuji Hayashi, Masashi Nakayama, Takahiro Kojima, Kenjiro Namikawa, Takao Fujisawa, Susumu Okano, Eisuke Hida, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino, Norio Nonomura
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Previous clinical trials have demonstrated the potential efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) in patients with cancer involving homologous recombination repair (HRR) gene-mutation. Moreover, HRR gene
Externí odkaz:
https://doaj.org/article/5f0dc8735dd54b21bcb309ee64c3e011
Autor:
Ryutaro Onaga, Tomohiro Enokida, Kazue Ito, Yuri Ueda, Susumu Okano, Takao Fujisawa, Akihisa Wada, Masanobu Sato, Hideki Tanaka, Naohiro Takeshita, Nobukazu Tanaka, Yuta Hoshi, Makoto Tahara
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundDespite advances in precision medicine, most patients with recurrent or metastatic salivary gland carcinoma still need conventional chemotherapies, such as the combination of taxane and platinum. However, evidence for these standardized reg
Externí odkaz:
https://doaj.org/article/4830b975dd4143c69ef643d2aa8f99b8
Autor:
Yuma Shibutani, Shinya Suzuki, Atsunobu Sagara, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Fumiaki Sato, Tetsuro Yumoto, Motohiko Sano, Toshikatsu Kawasaki, Makoto Tahara
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundProteinuria is the most frequent adverse event of lenvatinib use. However, the association between lenvatinib-induced proteinuria and renal dysfunction remains unclear.MethodsWe retrospectively reviewed medical records of patients with thyr
Externí odkaz:
https://doaj.org/article/bf2ddac6f23a4c23873e4afe40272e95
Autor:
Michiyo Mizuno, Ikuko Chiba, Toru Mukohara, Miki Kondo, Kazushi Maruo, Tomohiro Ohigashi, Miki Naruo, Yoshihiro Asano, Tatsuya Onishi, Hiroshi Tanabe, Rieko Muta, Saori Mishima, Susumu Okano, Masami Yuda, Ako Hosono, Yuri Ueda, Hiroko Bando, Hiroya Itagaki, Carol Estwing Ferrans, Tetsuo Akimoto
Publikováno v:
Contemporary Clinical Trials Communications, Vol 30, Iss , Pp 101035- (2022)
Background: The aim of the trial is to evaluate the effectiveness of interventions provided by online support program apps, adopting health-related quality of life (HR-QOL) scores as indicators. Methods: The design is as an open, randomized, parallel
Externí odkaz:
https://doaj.org/article/f42c280edfd14d53b2fc8ca342384431